A Food and Drug Administration advisory committee is set to meetFeb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agentfor colorectal cancer developed by Immunomedics. Immunomedics,of Morris Plains, NJ, has been working with the FDA on the
A Food and Drug Administration advisory committee is set to meet
Feb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agent
for colorectal cancer developed by Immunomedics. Immunomedics,
of Morris Plains, NJ, has been working with the FDA on the agent's
product license application (PLA) since the agency said the PLA
was not approvable in 1994 (SCAN 6/1/94).
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.